Company intelligence / Profile preview

Tau-MEDICAL Co., Ltd.

Israel

Ownership: Private
Development stage: Other

Overview

Alpha Tau Medical's Alpha DaRT technology has shown promising clinical results in recurrent and advanced skin and head & neck SCC, leading to FDA Breakthrough Device Designation. Expanded trials are underway for more indications such as GBM, pancreas, breast, and prostate cancer.

Therapeutic areas: Oncology
Modalities: DeviceRadiopharmaceutical (Alpha emitter-based local therapy)
Industry: Biotech

Partnerships

Numerous medical and educational institutions worldwide

Beyond the preview

Go deeper on Tau-MEDICAL Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tau-MEDICAL Co., Ltd..

Explore the full profile